Avita Medical (ASX:AVH) said researchers presented data at the annual meeting of the British Burn Association demonstrating reduced length of hospital stays among burn patients treated with the Recell system, according to a Tuesday Australian bourse filing.

The study, representing the largest real-world analysis of skin cell suspension autograft, or Recell, analyzed registry data from over 6,300 patients treated with Recell between 2019 and 2024.

For patients with burns covering less than 30% total body surface area, their hospital stay was reduced by 6.2 days or about 36% if they were treated with Recell Spray-On Skin Cells alone, compared with patients treated with split-thickness autografts.

The reduced lengths of stay led to cost savings of around AU$300 million over the five-year study period.

The session was titled "The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective," and the study was presented by Jeffrey Carter of Louisiana State University Health and Sciences Center and University Medical Center in New Orleans.